Navigation Links
Bioniche Provides a Corporate Update

BELLEVILLE, ON, April 27 /PRNewswire-FirstCall/ - Bioniche Life Sciences Inc. ("Bioniche"; TSX: BNC), a research-based, technology-driven Canadian biopharmaceutical company, today provided an update on its corporate activities.

One of the near-term objectives of the Company, as reported in previous financial disclosures, is the conclusion of a partnering transaction related to its Mycobacterial Cell Wall-DNA Complex (MCC), formulated as Urocidin(TM), for the intravesical treatment of non-muscle-invasive bladder cancer. While the Company has received significant interest in Urodicin from a number of potential partners, it has not yet finalized a transaction and the timeline for doing so has exceeded management's expectations. Given such delays and the Company's near-term cash needs, the Board of Directors has decided to broaden its fundraising strategies to include possible asset dispositions.

In addition, the Company has amended the maturity date of its existing secured revolving credit facility with Valens U.S. (formerly Laurus Master Funds) to June 30, 2009. Bioniche and Valens agreed to this extension to allow the Company time to identify new banking partner(s) after Valens decided to retrench its activities due to credit market conditions, as well as to allow the Company to execute its near-term corporate objectives. This amendment will replace the previously agreed "on demand" status, with an additional fee applicable at maturity of the facility.

The Company is also expanding internal cost cutting measures introduced during the past two fiscal quarters to help address its near-term liquidity requirements.

The Company expects to release its Fiscal 2009 third quarter financial results on May 6, 2009.

About Bioniche Life Sciences Inc.

Bioniche Life Sciences Inc. is a research-based, technology-driven Canadian biopharmaceutical company focused on the discovery, development, manufacturing, and marketing of proprietary products for human and animal health markets worldwide. The fully-integrated company employs approximately 200 skilled personnel and has three operating divisions: Human Health, Animal Health, and Food Safety. The Company's primary goal has been to develop proprietary cancer therapies supported by revenues from marketed products in human and animal health. Bioniche has been named one of the Top 50 Best Small and Medium-Sized Employers in Canada for 2009. For more information, please visit

Except for historical information, this news release may contain forward-looking statements that reflect the Company's current expectation regarding future events. These forward-looking statements involve risk and uncertainties, which may cause, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process, and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting.

SOURCE Bioniche Life Sciences Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Bioniche Completes Recruitment in First Phase III Clinical Trial with Urocidin(TM)
2. Bioniche Revolving Credit Facility Maturity Date Amended
3. Bioniche Phase II Bladder Cancer Trial Results Published in The Journal of Urology
4. Bioniche Warrants Expiration Date to be Extended
5. Bioniche Reports Fiscal 2009 Second Quarter
6. Bioniche Invited to Participate in Canadian Beef Value Chain Roundtable
7. Bioniche Named One of the Top 50 Best Small and Medium Employers in Canada
8. Bioniche Presents MCC Data at the SIU World Uro-Oncology Update in Santiago, Chile
9. Bioniche Reports Fiscal 2009 First Quarter
10. Bioniche Allows Conversion of Portion of Revolving Credit Facility
11. Bioniche Presents E. coli O157:H7 Vaccine Data to World Buiatrics Congress in Budapest, Hungary
Post Your Comments:
(Date:11/24/2015)... ... November 24, 2015 , ... ... announces Fragrance by Marcelle, a cosmetic invention which offers a combination of natural ... Market in the US is worth $3 billion annually," says Scott Cooper, CEO ...
(Date:11/24/2015)... , ... November 24, 2015 , ... ... the Business Action on Health Awards, bestowed annually to the world’s best corporate-supported ... commended companies at Global Health Council’s Landscape Symposium held in Washington D.C and ...
(Date:11/24/2015)... ... November 24, 2015 , ... The OSHA Training ... Institute Education Center in Northern California, is calling on retail employers to implement ... As the volume of sales and shoppers rapidly expands, retailers are strongly ...
(Date:11/24/2015)... ... 24, 2015 , ... There’s nothing better than giving the gift of green ... enjoy. , This year, gardens are popping up in the most unexpected places. ... , Vita Gardens’ African Keyhole Garden Bed ($499) , Water conscious gardeners – and ...
(Date:11/24/2015)... ... November 24, 2015 , ... Wireless Analytics, ... today announced new 24-hour weekday support capability. The “all hours” offering was ... Analytics’ international customers, and to enhance after-hours support available in the US. , ...
Breaking Medicine News(10 mins):
(Date:11/24/2015)... -- The uptake of recently approved and pipeline premium products ... market growth to 2021, says GBI Research . ... for Type 1 Diabetes Mellitus (T1DM), will be a key driver of ... --> The uptake of recently approved and pipeline premium ... of market growth to 2021, says GBI Research ...
(Date:11/24/2015)... 24, 2015   Renowned ... deliver s advice and insights on ... More than 50% of Dubai ... according to the DHA   femMED launches comprehensive solutions for ... Dubai residents are not consuming enough to keep ...
(Date:11/24/2015)...  Freudenberg Medical has developed specialty tubing for an inexpensive, ... facilities. Africa and ... Nevertheless, prompt diagnosis is important to treat those affected and ... the help of a portable mini-lab or "lab on a ... affected areas and perform rapid testing for HIV. They do ...
Breaking Medicine Technology: